prikaz prve stranice dokumenta Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?
  Preuzmi
PDF 889.92 KB
Znanstveni rad - Izvorni znanstveni rad
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?
Genes, 15 (2024), 5; 607. https://doi.org/10.3390/genes15050607
Ganoci, Lana; Palić, Jozefina; Trkulja, Vladimir; Starčević, Katarina; Šimičević, Livija; Božina, Nada; Lovrić-Benčić, Martina; Poljaković, Zdravka; Božina, Tamara

Citirajte ovaj rad

Ganoci, L., Palić, J., Trkulja, V., Starčević, K., Šimičević, L., Božina, N. ... Božina, T. (2024). Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?. Genes, 15. (5). doi: 10.3390/genes15050607

Ganoci, Lana, et al. "Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?." Genes, vol. 15, br. 5, 2024. https://doi.org/10.3390/genes15050607

Ganoci, Lana, Jozefina Palić, Vladimir Trkulja, Katarina Starčević, Livija Šimičević, Nada Božina, Martina Lovrić Benčić, Zdravka Poljaković i Tamara Božina. "Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?." Genes 15, br. 5 (2024). https://doi.org/10.3390/genes15050607

Ganoci, L., et al. (2024) 'Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?', Genes, 15(5). doi: 10.3390/genes15050607

Ganoci L, Palić J, Trkulja V, Starčević K, Šimičević L, Božina N, i sur.. Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?. Genes [Internet]. 10.05.2024. [pristupljeno 16.03.2025.];15(5). doi: 10.3390/genes15050607

L. Ganoci, et al., "Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?", Genes, vol. 15, br. 5, Svibanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:179018. [Citirano: 16.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:179018
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?
AutorLana Ganoci
AutorJozefina Palić
AutorVladimir Trkulja
AutorKatarina Starčević
AutorLivija Šimičević
AutorNada Božina
AutorMartina Lovrić-Benčić
AutorZdravka Poljaković
AutorTamara Božina
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MEDICINSKU KEMIJU, BIOKEMIJU I KLINIČKU KEMIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA NEUROLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA TEMELJNU I KLINIČKU FARMAKOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Farmakologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
A recently discovered haplotype—CYP2C:TG—determines the ultrarapid metabolism of several CYP2C19 substrates. The platelet inhibitor clopidogrel requires CYP2C19-mediated activation: the risk of ischemic events is increased in patients with a poor (PM) or intermediate (IM) CYP2C19 metabolizer phenotype (vs. normal, NM; rapid, RM; or ultrarapid, UM). We investigated whether the CYP2C:TG haplotype affected efficacy/bleeding risk in clopidogrel-treated patients. Adults (n = 283) treated with clopidogrel over 3–6 months were classified by CYP2C19 phenotype based on the CYP2C19*2*17 genotype, and based on the CYP2C19/CYP2C cluster genotype, and regarding carriage of the CYP2:TG haplotype, and were balanced on a number of covariates across the levels of phenotypes/haplotype carriage. Overall, 45 (15.9%) patients experienced ischemic events, and 49 (17.3%) experienced bleedings. By either classification, the incidence of ischemic events was similarly numerically higher in PM/IM patients (21.6%, 21.8%, respectively) than in mutually similar NM, RM, and UM patients (13.2–14.8%), whereas the incidence of bleeding events was numerically lower (13.1% vs. 16.6–20.5%). The incidence of ischemic events was similar in CYP2C:TG carries and non-carries (14.1% vs. 16.1%), whereas the incidence of bleedings appeared mildly lower in the former (14.9% vs. 20.1%). We observed no signal to suggest a major effect of the CYP2C19/CYP2C cluster genotype or CYP2C:TG haplotype on the clinical efficacy/safety of clopidogrel.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaGenes
Brojčani podacivol. 15, br. 5, 607
e-ISSN2073-4425
DOIhttps://doi.org/10.3390/genes15050607
URN:NBNurn:nbn:hr:105:179018
Datum objave publikacije2024-05-10
ProjektŠifra: UIP-2020-02-8189
Naziv (hrvatski): Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova
Naziv (engleski): Pharmacogenomics in prediction of cardiovascular drugs adverse reaction
Kratica: PGx-CardioDrug
Voditelj: Tamara Božina
Pravna nadležnost: Hrvatska
Financijer: Hrvatska zaklada za znanost
Linija financiranja: Installation Research Projects
URL dokumentahttps://www.mdpi.com/2073-4425/15/5/607
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2025-02-05 14:15:28